H. Lundbeck A/S, of Copenhagen, has acquired Abide Therapeutics Inc. in a deal designed to strengthen the Danish company's weakened pipeline and establish a research hub in the U.S.
Gilead Sciences Inc. missed its top-line numbers for the first quarter of the year but was bolstered by strong volume growth of its HIV franchise in the U.S. Its weakness came from lower sales for hepatitis C virus (HCV) drugs, down 21% from last year.
The FDA has approved Sanofi Pasteur Ltd.'s Dengvaxia vaccine to prevent dengue disease for children ages 9 through 16 with a previous dengue infection and who live in endemic areas of the U.S., including the territories of American Samoa, Guam, Puerto Rico and the U.S. Virgin Islands.
Vertex Pharmaceutical Inc. stood tall Tuesday as it announced first-quarter numbers that vaulted the company from a strong 2018 to an even more powerful new year as the top-line grew and the pipeline firmed up.
G1 Therapeutics Inc. plans to submit a marketing application for the U.S. next year based on FDA feedback from the company's end-of-phase II meeting for trilaciclib, a myelopreservation agent designed to protect bone marrow from damage from chemotherapy. The company expects to expand to Europe afterward.
While Immunomedics Inc. resolves issues posed by a complete response letter (CRL) regarding the antibody-drug conjugate sacituzumab govitecan for metastatic triple-negative breast cancer, the company announced a license agreement with Everest Medicines II Ltd. to develop, register and commercialize the drug in much of Asia outside of Japan.
While Immunomedics Inc. resolves issues posed by a complete response letter (CRL) regarding the antibody-drug conjugate sacituzumab govitecan for metastatic triple-negative breast cancer, the company announced a license agreement with Everest Medicines II Ltd. to develop, register and commercialize the drug in much of Asia outside of Japan.
Mateon Therapeutics Inc. and Oncotelic Inc. completed the merger they announced on April 17. Oncotelic becomes a wholly owned subsidiary of Mateon, and the combined company has a pipeline of TGF-beta RNA therapeutics for late-stage cancers, including gliomas, pancreatic cancer and melanoma.
Despite a better than expected first-quarter earnings report, Biogen Inc.'s stock (NASDAQ:BIIB) continued its drift downward Wednesday as shares traded 2.5% lower at the close, ending the day at $224.40.
Clinical-stage biotech Poseida Therapeutics Inc. received a boost Monday from a $142 million series C financing, most of which comes from Novartis AG. The funding goes toward Poseida's lead product, P-BCMA-101, which is enrolling patients for a phase II registrational trial.
